Navigation Links
Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
Date:6/24/2013

p>

About B-Cell Activating Factor (BAFF) and Blisibimod

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain, called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering.  Such statements are based on the Company's e
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 The Pharmaceutical Care Management ... managers (PBMs), today filed a lawsuit in ... Iowa law that restricts tools ... the state,s employers and consumers.  The ... severely restricting the use of Maximum Allowable Cost (MAC) ...
(Date:9/2/2014)... Spanien und CALGARY, Alberta , September ... Vorgestellt in der "State of the Art and Featured ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, ... bei Resverlogix, beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 ... gehalten hat. In seinem Vortrag mit dem Titel " ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... June 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) today announced results from a ... BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall ... that produce insulin.) Three years of BYETTA therapy improved ...
... June 25 Novo Nordisk today presented phase 2 ... which demonstrated the potential to help achieve target glycemic control when ... at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1) ... These ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 2Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 3
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Complications ... mastectomy and reconstruction, a new study indicates. ... mastectomy was associated with a slightly higher risk ... The study included more than 18,000 breast cancer ... a double mastectomy with breast reconstruction and were ...
(Date:9/2/2014)... who return to the emergency department within a few days ... their symptoms and have lost trust in other parts of ... study published online today in Annals of Emergency Medicine ... Perspective" ). , "When asked why they did ... their symptoms were too severe to wait until their scheduled ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Two new studies further confirm ... 6-year-olds who were breast-fed have a lower risk of ... while the other finds a similar trend when it ... benefits of breast-feeding in the immediate newborn period," said ... in New York City. She was not involved in ...
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Drinking and ... for teens, a new study suggests. Researchers analyzed ... U.S. high school seniors who said they had used ... found that drinking alcohol was associated with more unsafe ... and regret about actions while under the influence of ...
(Date:9/2/2014)... Albany, New York (PRWEB) September 02, 2014 ... lucrative business with products and services such as ... color, radio frequency-device based treatments, and breast augmentation ... market report published by U.S.-based market intelligence firm ... anti-aging treatments and products will grow to USD ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3
... ... have come together in a new format from Einstein Medical. A completely ... to create and support a rapidly evolving category: non-insurance reimbursed medicine. All ... practice, converting new patients, keeping existing patients, and better patient care. The ...
... Dr. ... announces the ten-year anniversary of his involvement with the Smiles for Life program. This annual ... to charities. , ... New York (Vocus) April 10, 2010 -- A dentist in a small community in upstate ...
... ... Dr. Jeffrey Raval has pioneered a new process to make the injections in this liquid ... that the FDA approved in 2009. , ... Denver, Colo. (PRWEB) April 10, 2010 -- As an injector trainer, one of ...
... ... ... Arizona School of Health Sciences (ATSU-ASHS) held its spring commencement ceremony for four ... earned a master of science or doctoral degree in Human Movement, Physician Assistant Studies, Audiology, ...
... guesswork, researchers say , FRIDAY, April 9 (HealthDay News) -- ... the vaccines contained both strains of influenza B instead of ... "Adding a second influenza B virus strain to the seasonal ... strain selection and help improve the vaccine,s ability to prevent ...
... , ... developer for his own use, this hand polished and sculpted mouse pad is now available ... functional addition to any desktop. , ... (PRWEB) April 9, 2010 -- Dxtra Announces the availability of the world,s only solid ...
Cached Medicine News:Health News:LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series 2Health News:LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series 3Health News:LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series 4Health News:Ballston Lake Cosmetic Dentist Excited about 10th Year Participating in Smiles for Life Program 2Health News:Ballston Lake Cosmetic Dentist Excited about 10th Year Participating in Smiles for Life Program 3Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 2Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 3Health News:ATSU –ASHS Holds Spring Commencement Ceremony 2Health News:Flu Vaccine With Both B Strains May Offer Better Protection 2
Used to introduce large devices for vascular intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Portless Sheath Introducers...
Medicine Products: